曲克芦丁脑蛋白水解物治疗颅脑损伤的循证药物经济学评价

Evidence-based pharmacoecomics evaluation of Troxerutin and Cerebroprotin Hydrolysate Injection in the treatment of craniocerebral injury

目的:从医保支付方角度,评估曲克芦丁脑蛋白水解物注射液治疗颅脑损伤的经济性。方法:基于现有文献,对曲克芦丁脑蛋白水解物注射液和依达拉奉注射液治疗颅脑损伤的预后良好率进行间接比较。在此基础上,比较曲克芦丁脑蛋白水解物注射液和依达拉奉注射液治疗颅脑损伤的药品成本。结果:曲克芦丁脑蛋白水解物注射液联合常规治疗vs常规治疗治疗颅脑损伤的预后良好率分别为82. 30%(175/213)、58. 10%(63/108),有统计学差异(P <0. 05);依达拉奉注射液联合常规治疗vs常规治疗治疗颅脑损伤预后良好率分别为72. 05%(531/737)和49. 22%(348/707),有统计学差异[OR=2. 78,95%CI(2. 22,3. 48),P <0. 01];曲克芦丁脑蛋白水解物注射液联合常规治疗vs依达拉奉注射液联合常规治疗治疗颅脑损伤的预后良好率无统计学差异[OR=1. 15,95%CI(0. 56,2. 41)]。最小成本分析结果:曲克芦丁脑蛋白水解物(2,5和10 mL)和依达拉奉注射液(10 mg∶5 mL)每疗程用药费用分别为3 311. 7,2 752. 96,2 361. 38和3 557. 4元,药品费用差分别为-245. 7,-804. 44和-1 196. 02元。结论:假设其他费用如检查费用、常规治疗费用、住院费用以及不良反应处理费用等相同,颅脑损伤患者使用曲克芦丁脑蛋白水解物注射液和依达拉奉注射液的预后良好率无统计学差异。在此基础上,颅脑损伤患者使用曲克芦丁脑蛋白水解物注射液比使用依达拉奉注射液药品治疗费用低。

Objective: To evaluate the cost-effectiveness of injection of Troxerutin and Cerebroprotin Hydrolysate Injection in the treatment of craniocerebral injury from the perspective of medical insurance. Methods : The rates of favorable prognosis of patients with craniocerebral injury who received injection of Troxerutin and Cerebroprotin Hydrolysate Injection or edaravone injection of were compared based on the existing literature. Then the medical costs of the two regimens were calculated and compared. Results: The difference in the rate of favorable prognosis between Qu Ke group and regular treatment were statistically significant ( 82. 30%( 175/213 ) vs 58. 10%(63/108 ), P≤0. 05 ), and so was the edaravone group [ 72. 05%( 531/737 ) vs 49. 22%( 348/707 ), OR = 2. 78 ,95% CI ( 2. 22 , 3. 48 ), P < 0. 01 ], while the rates of favorable prognosis of QuKe group and edaravone group were not statistically different ( OR = 1. 15,95% CI ( 0. 56 , 2.41 ). The minimum cost analysis showed that the drug costs per treatment of Troxerutin and Cerebroprotin Hydrolysate Injection (2,5 and 10 mL) and edaravone injection ( 10 mg: 5 mL) were 3 311.7 , 2 752. 96 , 2 361.38 and 3 557. 4 yuan , and the differences were - 245. 7 ,-804. 44 and -1 196. 02 yuan , respectively. Conclusion : Assuming that the other expenses such as the cost of inspection , regular treatment expenses, hospitalization expenses and the treatment cost of adverse reactions are the same for different therapeutic regimens, the medication cost of hydrolysate of lubutin will be lower than edaravone for the treatrne nt of craniocerebral in jury, based on the evidence that the rates of favorable prognosis of the two drugs had no statistical difference.